Akums Unveils New Sterile Facility for Lyophilised Products and Injectables

Akums Drugs and Pharmaceuticals revealed the launch of a new sterile facility focused on manufacturing lyophilised products and injectables, alongside vials, ampoules, eye and ear drops, and form-fill-seal (FFS) products. Lyophilisation involves removing water from drug particles at low temperatures, ensuring the drug's effectiveness and extending the stability and shelf life of pharmaceutical products, particularly fragile chemical compounds.

The firm indicated that its foray into this niche market, marked by substantial entry hurdles and reduced competition, offers considerable chances to innovate and address specialized therapeutic requirements.

“By entering this space, Akums aims to meet the growing global demand for these products,” it added.

The facility's goal is to equip Akums to address the increasing global demand and facilitate large-scale production in various therapeutic fields. This advancement occurs as the contract drug manufacturing (CDMO) firm emphasizes expanding capacity following its public listing in September of the previous year. The worldwide market for lyophilised injectables, valued at around $3,365.4 million in 2023, is anticipated to grow steadily, hitting $4,978.3 million by 2030.

“With a compound annual growth rate (CAGR) of 5.6 per cent during the forecast period, this market demonstrates strong potential driven by increasing demand for products requiring enhanced stability and extended shelf life,” Akums added.